Le Lézard
Classified in: Health, Science and technology, Business
Subject: FNC

424 Capital Announces Investment in VaLogic


WAKEFIELD, Mass., Nov. 29, 2023 /PRNewswire/ -- 424 Capital announced today that it has completed a significant investment in VaLogic, a leading provider of GMP (Good Manufacturing Practice) and GLP (Good Laboratory Practice) compliance software and services based in Frederick, MD. This strategic move by 424 Capital aims to expedite positive clinical outcomes by enabling pharmaceutical and biotechnology organizations to focus on the research, development, and production of cutting-edge therapeutics in a compliant and effective manner.

Founded in 2001 by CEO Bill Robertson, VaLogic provides a comprehensive range of software and compliance services to the life science and biotechnology market. These services help organizations and facilities maintain GMP compliance and enact high standards while focusing on advancing life-saving therapeutics.

VaLogic offers advisory and facility design, full commissioning and qualification, cleanroom environmental monitoring, HEPA/cleanroom certifications, calibration, preventative maintenance, and a proprietary SaaS software called LogiPointtm for continuous monitoring of critical facilities and equipment.

The partnership with 424 Capital is an important milestone in VaLogic's business growth and expansion plans. It further supports progress in the biotechnology, life sciences, and pharmaceutical industries.

"This is a momentous occasion for VaLogic as we celebrate our long and successful journey and prepare for future growth. We are thrilled to announce our new business partnership, which will enable us to pursue our strategic goals, expand into new markets and attract new clients. It will also allow us to offer a wider range of services in our current and emerging areas of expertise. We take pride in our talented teams who will continue to deliver high-quality service to our clients. Additionally, we are excited about the increased career opportunities this partnership will bring for our employees. As we enter 2024 and beyond, this partnership presents a tremendous opportunity for us to achieve our vision of growth and excellence," said Bill Robertson, CEO of VaLogic.

"424 Capital seeks to invest in important mission-driven companies, and VaLogic provides vital technology and services to clients in the life science and biotechnology sectors. We are excited to support the team in their ambition to scale their services and enable VaLogic's customers to accelerate cures and therapies in many critical healthcare disciplines," added Brennan Mulcahey, Managing Partner at 424 Capital.

The partnership between VaLogic and 424 Capital is expected to have a significant impact on early-stage life science and biotechnology companies, expediting research, product development, and production.

About VaLogic
VaLogic is a reliable and trusted partner for GxP compliance. VaLogic offers a wide range of services, including calibration, CQV (Commissioning, Qualification, and Validation), environmental monitoring, and certification. The specialization in pharmaceuticals, biotechnology, and life sciences ensures guaranteed unwavering compliance, operational efficiency, and excellence. For more information on VaLogic, please visit valogicbio.com.

About 424 Capital
424 Capital is a capital partner that invests in lower middle market companies in the tech enabled services space. 424 Capital works in partnership with founders and management teams to accelerate and scale for long-term growth. 424 invests in, empowers, and enables companies to step up, stand out, and make a difference in the world. For more information about 424 Capital, please visit 424capital.com.

VaLogic
Jeff Wells
[email protected]

424 Capital
Carol Li
[email protected]

SOURCE 424 Capital


These press releases may also interest you

at 03:44
21st.BIO unveiled a new pilot plant facility in its Danish...

at 03:05
Kindeva Drug Delivery (Kindeva), a global leader in drug-device combination products, today announced its investment in a second manufacturing line for the production of pressurized metered-dose inhaler (pMDI) products containing low-GWP (Global...

at 03:05
Lantern Pharma Inc. , a leading artificial intelligence (AI) oncology drug discovery and development company, today announced a strategic AI-driven collaboration with French biotechnology company, Oregon Therapeutics to optimize the development of...

at 03:00
Patients with spinal cord injury (SCI) could benefit from future treatment to repair nerve connections using red and near-infrared light....

at 03:00
A recent global survey conducted by the World Lupus Federation reported that 91% of survey respondents were taking or have taken oral steroids to treat their lupus. Over 7,700 people living with lupus from more than 100 countries participated in the...

at 02:11
Calliditas Therapeutics AB ("Calliditas") today announced data from the proof-of-concept Phase 2 trial evaluating setanaxib, its lead NOX enzyme inhibitor, in combination with pembrolizumab, in patients with squamous cell carcinoma of the head and...



News published on and distributed by: